MOMETASONE GENPAR AQUEOUS NASAL SPRAY mometasone furoate 50 microgram/actuation (as monohydrate) suspension spray bottle

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

mometasone furoate monohydrate, Quantity: 51.73 microgram/actuation (Equivalent: mometasone furoate, Qty 50 microgram/actuation)

Disponible desde:

Arrotex Pharmaceuticals Pty Ltd

Designación común internacional (DCI):

mometasone furoate monohydrate

formulario farmacéutico:

Spray, suspension

Composición:

Excipient Ingredients: glycerol; sodium citrate dihydrate; benzalkonium chloride; citric acid monohydrate; polysorbate 80; microcrystalline cellulose; carmellose sodium

Vía de administración:

Nasal

Unidades en paquete:

10 g of suspension (60 actuations), 16 g of suspension (120 actuations), 18 g of suspension (140 actuations) x 2, 18 g of suspension (140 actuations)

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Mometasone aqueous nasal spray 0.05% is indicated for the treatment of symptoms associated with seasonal allergic rhinitis and perennial allergic rhinitis and the prophylaxis of seasonal allergic rhinitis in adults, adolescents and children between the ages of 3 and 11 years.,Mometasone aqueous nasal spray 0.05% is also indicated for the treatment of nasal polyps in adult patients 18 years of age and older.,Mometasone aqueous nasal spray 0.05% is indicated for the treatment of symptoms associated with acute rhinosinusitis in patients 12 years of age and older without signs or symptoms of severe bacterial infection.

Resumen del producto:

Visual Identification: White to off-white viscous suspension.; Container Type: Bottle, with integral pump - manual actuated; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Estado de Autorización:

Licence status A

Fecha de autorización:

2016-01-06